Vanguard Global Advisers
PCVX icon

Vanguard Global Advisers’s Vaxcyte PCVX Stock Holding History

Vanguard Global Advisers’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.89M Sell
49,787
-1,863
-4% -$101K ﹤0.01% 1027
2026
Q1 		$3M Buy
+51,650
New +$2.8M ﹤0.01% 969

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Global Advisers's PCVX Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Vaxcyte (PCVX) stake by 3.6% in Q2 2026, selling an estimated $101K and leaving 49,787 shares worth $2.89M. The position accounts for ﹤0.01% of the portfolio, ranked #1027.

Vanguard Global Advisers first reported a position in PCVX in Q1 2026 and has held it in 2 quarters since. The position peaked at $3M in Q1 2026. 326 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Vanguard Global Advisers held 49,787 shares of Vaxcyte worth $2.89M as of Q2 2026.
  • Vanguard Global Advisers sold 1,863 Vaxcyte shares in Q2 2026, an estimated $101K.
  • Vaxcyte made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1027 holding.
  • Vanguard Global Advisers first reported a position in Vaxcyte in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Vaxcyte position peaked at $3M in Q1 2026.
  • 326 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.